FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Yahoo25 Jan 2022
Mind Medicine, a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.
Read the full story here.
looks like they finally got the trial cleared.
would REALLY like to know the pharmacology/what is "optimized" about MM-120?
Last edited by a moderator: